Patient characteristics (N = 52)
| Characteristic . | N . |
|---|---|
| Median age, y (range) | 52 (18-70) |
| ≥ 60 (%) | 8 (15) |
| Sex (%) | |
| Male | 22 (42) |
| Female | 30 (58) |
| ECOG performance status (%) | |
| 0 | 29 (55.8) |
| 1 | 12 (23.1) |
| 2 | 3 (5.8) |
| Unknown | 8 (15.4) |
| AML source (%) | |
| De novo AML | 43 (82.7) |
| Therapy related | 4 (7.7) |
| Prior MDS/MPD | 6 (11.5) |
| Cytogenetic risk category (%) | |
| Favorable | 7 (13.5) |
| Intermediate | 29 (55.8) |
| Poor | 16 (30.8) |
| Peripheral blood (range) | |
| WBC, mean in K/mcL | 7.7 ± 9.8 (3-40.5) |
| PB blast, mean % | 19 ± 23.5 (9-89) |
| Prior transplantation (%) | |
| Autologous | 3 (5.8) |
| Allogeneic | 6 (11.5) |
| Treatment indication (%) | |
| Primary refractory to 1 induction | 8 (15.4) |
| Primary refractory to 2+ inductions | 3 (5.8) |
| First relapse, first salvage | 37 (71.2) |
| CR1 < 6 mo | 12 |
| CR1 < 12 mo | 26 |
| First relapse, ≤ second salvage | 3 (5) |
| Second relapse | 1 (1.9) |
| Characteristic . | N . |
|---|---|
| Median age, y (range) | 52 (18-70) |
| ≥ 60 (%) | 8 (15) |
| Sex (%) | |
| Male | 22 (42) |
| Female | 30 (58) |
| ECOG performance status (%) | |
| 0 | 29 (55.8) |
| 1 | 12 (23.1) |
| 2 | 3 (5.8) |
| Unknown | 8 (15.4) |
| AML source (%) | |
| De novo AML | 43 (82.7) |
| Therapy related | 4 (7.7) |
| Prior MDS/MPD | 6 (11.5) |
| Cytogenetic risk category (%) | |
| Favorable | 7 (13.5) |
| Intermediate | 29 (55.8) |
| Poor | 16 (30.8) |
| Peripheral blood (range) | |
| WBC, mean in K/mcL | 7.7 ± 9.8 (3-40.5) |
| PB blast, mean % | 19 ± 23.5 (9-89) |
| Prior transplantation (%) | |
| Autologous | 3 (5.8) |
| Allogeneic | 6 (11.5) |
| Treatment indication (%) | |
| Primary refractory to 1 induction | 8 (15.4) |
| Primary refractory to 2+ inductions | 3 (5.8) |
| First relapse, first salvage | 37 (71.2) |
| CR1 < 6 mo | 12 |
| CR1 < 12 mo | 26 |
| First relapse, ≤ second salvage | 3 (5) |
| Second relapse | 1 (1.9) |
ECOG indicates Eastern Cooperative Oncology Group; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease; WBC, white blood cell count; PB, peripheral blood; and CR, complete remission.